APA (7th ed.) Citation

Isa, F., Forleo-Neto, E., Meyer, J., Zheng, W., Rasmussen, S., Armas, D., . . . Herman, G. A. (2022). Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. International journal of infectious diseases, 122, 585-592. https://doi.org/10.1016/j.ijid.2022.06.045

Chicago Style (17th ed.) Citation

Isa, Flonza, et al. "Repeat Subcutaneous Administration of Casirivimab and Imdevimab in Adults Is Well-tolerated and Prevents the Occurrence of COVID-19." International Journal of Infectious Diseases 122 (2022): 585-592. https://doi.org/10.1016/j.ijid.2022.06.045.

MLA (9th ed.) Citation

Isa, Flonza, et al. "Repeat Subcutaneous Administration of Casirivimab and Imdevimab in Adults Is Well-tolerated and Prevents the Occurrence of COVID-19." International Journal of Infectious Diseases, vol. 122, 2022, pp. 585-592, https://doi.org/10.1016/j.ijid.2022.06.045.